Wellness
Why We Choose STRIVE
We opt for Strive Compounding Pharmacy for our GLP1 medications due to their exceptional commitment to patient satisfaction. Strive’s quality control process is rigorous, with 26 additional testing cycles compared to standard pharmacies. This extensive testing assures us that the products we prescribe are both safe and effective.
A key advantage of Strive is its unique formulation of GLP1 medications. Both their semaglutide and tirzepatide compounds are enhanced with two beneficial additives:
1. Glycine: This addition is designed to help maintain muscle mass. We understand the effort you’ve put into achieving your current physique, and the inclusion of Glycine aims to preserve your hard-earned muscle during the weight loss.
2. Vitamin B12: A small amount is incorporated to potentially boost energy levels.
By selecting Strive, we ensure you receive high-quality GLP1 medications with thoughtful enhancements to support your overall health and weight management goals.
Semaglutide is a synthetic version of a naturally occurring hormone, classified as a GLP-1 analog. Its primary functions include boosting insulin production, reducing glucagon secretion, and influencing brain areas responsible for appetite regulation and food intake. A slight molecular modification allows semaglutide to remain active in the body for weeks, unlike the body’s natural version which lasts only minutes.
Semaglutide operates through several pathways:
- Slows gastric emptying, promoting a feeling of fullness with smaller meals
- Decreases intestinal motility, prolonging satiety
- Lowers blood sugar levels, partly by reducing hepatic glucose production
- Stimulates pancreatic insulin secretion
- Reduces systemic inflammation, leading to adiponectin release and fat breakdown
- Appetite and craving reduction
- Weight loss
- Improved blood glucose control
Dosing Protocol
Semaglutide treatment typically follows a gradual dose escalation:
- Weeks 1-4: 0.25 mg (5 units)
- Weeks 5-8: 0.50 mg (10 units)
- Weeks 9-12: 1.0 mg (20 units)
- Weeks 13-16: 1.75 mg (35 units)
- Weeks 16+: 2.5 mg (50 units)
Common side effects include nausea and constipation. Less frequent effects may include acid reflux, abdominal discomfort, vomiting, and diarrhea. If you experience these symptoms, please inform your healthcare provider as it may indicate the need for a dosage adjustment.
Serious side effects are more likely in patients with conditions such as hypoglycemia, kidney problems, or a history of allergic reactions. Semaglutide is not suitable for type 1 diabetes or diabetic ketoacidosis. It should not be combined with other GLP-1 medications.
Caution: Patients with a personal or family history of Multiple Endocrine Neoplasia Syndrome Type 2 or Medullary Thyroid Cancer should avoid semaglutide due to the risk of thyroid c-cell tumors. Those with a history of pancreatitis should consult their healthcare provider before use.
Tirzepatide is an innovative, once-weekly injectable medication that acts as both a GLP-1 receptor agonist and a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Like semaglutide, it enhances insulin production, reduces glucagon secretion, and targets appetite-regulating brain areas. Its modified structure allows for an extended duration of action.
Tirzepatide works through multiple mechanisms:
- Delays gastric emptying, promoting satiety with smaller portions
- Slows intestinal motility, extending the feeling of fullness
- Lowers blood sugar by reducing hepatic glucose production
- Stimulates pancreatic insulin secretion
- Increases energy expenditure through GIP receptor activation, contributing to weight loss
Primary Benefits
- Reduced appetite and food cravings
- Significant weight loss
- Improved A1C levels
- Enhanced cardiometabolic measures
Tirzepatide Dosing Schedule
The typical dose escalation for tirzepatide is as follows:
- Weeks 1-4: 2.5 mg (25 units)
- Weeks 5-8: 5 mg (50 units)
- Weeks 9-12: 7.5 mg (75 units)
- Weeks 13-16: 10 mg (100 units)
- Weeks 21-24: 15 mg (150 units)
The side effect profile of tirzepatide is similar to semaglutide. Common effects include nausea and constipation, with less frequent occurrences of acid reflux, abdominal pain, vomiting, and diarrhea. Inform your healthcare provider if you experience these symptoms, as they may indicate a need for dosage adjustment.
The risk of serious side effects is elevated in patients with hypoglycemia, kidney issues, or a history of allergic reactions. Tirzepatide is not appropriate for type 1 diabetes or diabetic ketoacidosis and should not be used alongside other GLP-1 medications.
Important: Patients with a personal or family history of Multiple Endocrine Neoplasia Syndrome Type 2 or Medullary Thyroid Cancer should not use tirzepatide due to the risk of thyroid c-cell tumors. Those with a history of pancreatitis should consult their healthcare provider before starting treatment.
Get in Touch
Fill out the form below and we will contact you as soon as possible